Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print May 25, 2005, doi:10.1212/01.WNL.0000166950.35189.5E)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
01.WNL.0000166950.35189.5Ev1
64/12/2029    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in Neurology
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thompson, J. A.
Right arrow Articles by Bale, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, J. A.
Right arrow Articles by Bale, J. F., Jr
Related Collections
Right arrow Bacterial infections
Right arrow All Neuromuscular Disease
Right arrow Anterior nerve cell disease
NEUROLOGY 2005;64:2029-2032
© 2005 American Academy of Neurology
Views & Reviews

Infant botulism in the age of botulism immune globulin

J. A. Thompson, MD, F. M. Filloux, MD, C. B. Van Orman, MD, K. Swoboda, MD, P. Peterson, PNP, S. D. Firth, PhD, MPH and J. F. Bale, Jr, MD

From the Division of Pediatric Neurology, Department of Pediatrics, The University of Utah and Primary Children’s Medical Center, Salt Lake City.

Address correspondence and reprint requests to Dr. Joel A. Thompson, Division of Pediatric Neurology, Primary Children’s Medical Center, Salt Lake City, UT 84113; e-mail: joel.thompson{at}hsc.utah.edu

Infant botulism causes acute bulbar dysfunction, weakness, and respiratory failure in infants living in endemic regions of the United States. Until Food and Drug Administration approval of botulism immune globulin (BIG) in October 2003, management of infant botulism had changed little since the 1970s. Currently, IV therapy with BIG is advised to shorten the duration and diminish the potential complications of the disorder. This review describes two decades of experience with infant botulism and provides a contemporary perspective on the role and benefit of BIG.

Received June 24, 2004. Accepted in final form March 18, 2005.


Related articles in Neurology:

June 28 Highlight and Commentary: Infant botulism: Epidemiology and treatment with BIG

Neurology 2005 64: 1993. [Full Text]  



This article has been cited by other articles:


Home page
 J Child NeurolHome page
L. Tseng-Ong and W. G. Mitchell
Infant Botulism: 20 Years' Experience at a Single Institution
J Child Neurol, December 1, 2007; 22(12): 1333 - 1337.
[Abstract] [PDF]

Home page
 PediatricsHome page
K. Underwood, S. Rubin, T. Deakers, and C. Newth
Infant Botulism: A 30-Year Experience Spanning the Introduction of Botulism Immune Globulin Intravenous in the Intensive Care Unit at Childrens Hospital Los Angeles
Pediatrics, December 1, 2007; 120(6): e1380 - e1385.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. Lindstrom and H. Korkeala
Laboratory Diagnostics of Botulism
Clin. Microbiol. Rev., April 1, 2006; 19(2): 298 - 314.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.